Kalbe Farma Tbk. PT (LCLA)
Market Closed
12 Jun, 20:00
XMUN 
€
0. 04
+0
+2.8571%
€
4.61B Market Cap
- P/E Ratio
0.01% Div Yield
0 Volume
0 Eps
€ 0.04
Previous Close Want to track LCLA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
LCLA closed today higher at €0.04, an increase of 2.8571% from yesterday's close, completing a monthly decrease of -20% or -€0.01. Over the past 12 months, LCLA stock lost -40.9836%.
The next announced payment will be in In 1 weeks on Jun 24, 2026 for a total of €20.
The last earnings report, released on Apr 28, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Kalbe Farma Tbk. PT has completed 2 stock splits, with the recent split occurring on Oct 08, 2012.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on IDX (IDR).
LCLA Chart
People also search for
Kalbe Farma Tbk. PT (LCLA) FAQ
What is the stock price today?
The current price is €0.04.
On which exchange is it traded?
Kalbe Farma Tbk. PT is listed on XMUN.
What is its stock symbol?
The ticker symbol is LCLA.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0.01%.
What is its market cap?
As of today, the market cap is 4.61B.
Has Kalbe Farma Tbk. PT ever had a stock split?
Kalbe Farma Tbk. PT had 2 splits and the recent split was on Oct 08, 2012.
Kalbe Farma Tbk. PT Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | - CEO | XMUN Exchange | ID1000125107 ISIN |
| Indonesia Country | 12,784 Employees | 4 Jun 2026 Last Dividend | 8 Oct 2012 Last Split | - IPO Date |
Kalbe Farma Tbk. PT is a prominent pharmaceutical corporation in Indonesia known for its extensive range of healthcare products and services. As a leader in the pharmaceutical industry, its primary function is the research, production, and distribution of prescription and over-the-counter medications, supplements, and medical devices. The company plays a vital role in advancing healthcare accessibility in Indonesia and other Southeast Asian markets. Kalbe Farma significantly impacts the pharmaceutical, healthcare, and consumer health goods sectors by developing innovative health solutions and maintaining a strong retail presence across the region. Its broad product portfolio addresses numerous medical needs, from specialist prescription drugs to nutritional products, fostering better health outcomes. Founded in 1966 and headquartered in Jakarta, Kalbe Farma has grown to become a key player in the regional pharmaceutical landscape. Its diverse operations, strategic alliances, and investment in R&D underscore its commitment to improving health standards and meeting the evolving demands of the healthcare market.
Contact Information
Address: Gedung KALBE
Phone: 62 21 4287 3888
Website: https://www.kalbe.co.id
